Supplementary Data from Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use
Year: 2023
Type: supplementary-materials
Abstract: Tables S1-S5, Figures S1, S2 Supplementary Table S1. Summary of prior systemic cancer therapies in {greater than or equal to}2% of patients with prior cetuximab exposure Supplementary Table S2. Summary of prior systemic cancer therapies in {greater than or equal to}2% of patients without prior cetuximab exposure Supplementary Table S3. Summary of prior cetuximab-containing regimens in all treated patients Supplementary Table S4. Treatment-related adverse events by prior cetuximab exposure reported in {greater than or equal to}10% of patients in any subgroup Supplementary Table S5. Select treatment-related adverse events by prior cetuximab exposure Supplementary Figure S1. CONSORT diagram. Supplementary Figure S2. Best reduction from baseline in target lesions among patients treated with nivolumab.
Authors: Robert L. Ferris, Lisa Licitra, Jerome Fayette, Caroline Even, George Blumenschein, Kevin J. Harrington, Joel Guigay, Everett E. Vokes, Nabil F. Saba, Robert Haddad, Shanmugasundaram Ramkumar, Jeffery Russell, Peter Brossart, Makoto Tahara, A. Dimitrios Colevas, Fernando Concha-Benavente, Mark Lynch, Li Li, Maura L. Gillison
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361933462